Telotristat etiprate is an investigational oral agent for carcinoid syndrome now being studied in the TELESTAR clinical trial.
TELESTAR is a global Phase III clinical trial specifically designed for patients whose carcinoid syndrome is not adequately controlled by their current somatostatin analog therapy.
The TELESTAR trial
is now ENROLLING
To learn more, contact us at:
1-855-897-0125 (US and Canada)
Be sure to include your country's exit
code, such as +00 for the EU